Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the?enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Candel Therapeutics Inc.

Canaccord Genuity analyst John Newman maintained a Buy rating on Candel Therapeutics today and set a price target of $25.00. Newman covers the Heal...

Current Quarter	$-0.24	Next Quarter	$NA
Current Year	$-0.4	Next Year	$-0.48
QoQ Growth	NaN%	YoY Growth	-20.0%
3Y EPS CAGR	+3.1%	Target Price	$19.43
Consensus	Buy	Upside	+327.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CADL	$4.55	+2.94%	745.50K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CADL	$4.55	+2.9%	745.50K
3
4
5
6

CADL

CADL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Candel Therapeutics Inc. Data in Excel

Get Candel Therapeutics Inc. Data in Excel